Potential clinical relevance |
A |
No inconvenience, insignificant effect |
B |
Short-lived inconvenience (<24–48 h) without residual symptoms |
C |
Long-lived inconvenience (48–168 h) without residual symptoms |
D |
Long-lived inconvenience (>168 h) with residual symptoms or handicap |
E |
Potential failure of life-saving therapy, increased risk of pregnancy (without risks concerning mother and/or fetus), cardiac arrhythmia, rhabdomyolysis, malignant hypertension, pseudopheochromocytome, multiorgan failure |
F |
Death, torsade de pointes, ventricular arrhythmia, myocardial infarction, serotonin syndrome, hyperpyrexia (42°C) |
Quality of evidence |
4 |
Controlled, published study with clinically relevant end-points |
3 |
Controlled, published study with relevant surrogate end-points |
2 |
Well-documented, published case reports; analysis of case series |
1 |
Incomplete, published case reports |
0 |
Animal studies, in vitro studies, data on file |
- |
No evidence |
|
Not classified |